Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Achilles Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Achilles Therapeutics announced earnings per share of $-0.32 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.59 on revenue of $0.
Achilles Therapeutics 's are down 35% and is trading at $1.79 , still down 75.24% from its 52 week high of $7.23 set on Tuesday, November 9, 2021.
Achilles Therapeutics shares lost 10.05% to trade at $1.79 in intra-day trade the report.
Achilles Therapeutics follows other major Healthcare sector earnings this month
Achilles Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar